Levonorgestrel effects on serum androgens, sex hormone–binding globulin levels, hair shaft diameter, and sexual function
Objective
To determine the effects of levonorgestrel (LNG) on serum androgens, sex hormone–binding globulin (SHBG), hair shaft diameter, and sexual function in women.
Design
Substudy of a prospective randomized double-blind study in women using an LNG SC implant (LNG-SI), who were treated with doxycycline or placebo.
Setting
Medical school department of obstetrics and gynecology.
Patient(s)
Forty women were enrolled; 36 completed the study.
Intervention(s)
Participants were randomized to doxycycline 20 mg or an identical placebo orally twice a day after LNG-SI insertion.
Main Outcome Measure(s)
Serum levels of total T (TT), free T (FT), androstenedione (A), dehydroepiandrosterone sulfate (DHEAS), dihydrotestosterone (DHT), androstanediol glucuronide (AG), SHBG, and LNG; hair shaft diameter; and sexual function using the Brief Index of Sexual Function for Women and the Arizona Sexual Experiences Scale were assessed.
Result(s)
Serum TT, A, DHT, DHEAS, and SHBG declined after LNG-SI insertion. No changes were found in FT, AG, hair shaft diameter, or sexual function. Serum LNG correlated with SHBG levels. There were no differences between the placebo and doxycycline groups.
Conclusion(s)
LNG reduced serum TT, A, DHT, DHEAS, and SHBG but had no effect on sexual function or markers of androgen bioactivity.
Key Words: Levonorgestrel subcutaneous implant, sex hormone–binding globulin, serum androgens, hair shaft diameter, sexual function, testosterone
To access this article, please choose from the options below
G.K. has nothing to disclose. S.A.B. has nothing to disclose. F.Z.S. has nothing to disclose. J.L. has nothing to disclose. J.C. has nothing to disclose. D.F.A. has consulted for Abbott Laboratories, Agile Therapeutics, Bayer Healthcare, Berlex, ConCert Pharmaceutical, Novo Nordisk, Radius, Schering Plough, Warner Chilcott, and Wyeth Laboratories; received research support from Bayer, Duramed, Organon-Schering Plough, Solvay, Warner Chilcott, and Wyeth; and received lecture fees from Novo Nordisk, Organon-Schering Plough, Solvay, Upsher-Smith, and Wyeth.
This study was supported by National Institute of Child Health and Human Development grant no. R01 HD43175-01.
PII: S0015-0282(08)04798-5
doi:10.1016/j.fertnstert.2008.12.095
© 2010 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

